Separate validations were performed in 3,968 samples for ERBB2 amplification in breast cancer as a complement to the MI Cancer Seek tumor profiling validation, and in 9,213 samples for ALK fusions in NSCLC. This evidence concerns the gene ALK and breast carcinoma.